TVTX: Guggenheim Raises Target
Guggenheim analyst Vamil Divan maintains a Buy rating on Travere Therapeutics and raises the price target to $65
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
TVTX: Guggenheim Raises PT
Guggenheim analyst Vamil Divan raises price target on Travere Therapeutics to $65 and keeps Buy rating ahead of Q2 earnings